Tvardi Therapeutics Inc (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting the STAT3 signaling pathway. The company has no product revenue and funds operations through capital markets activity, reporting a net loss of $18.2 million for the year ended December 31, 2025, compared to a net loss of $29.4 million for the year ended December 31, 2024. Its lead asset, TTI-101, is in clinical development across three indications: hepatocellular carcinoma (HCC), idiopathic pulmonary fibrosis (IPF), and metastatic breast cancer (mBC). Direct R&D spending on TTI-101 for HCC totaled $3.2 million in FY2025, down from $8.6 million in FY2024. IPF spending was $4.7 million in FY2025 versus $6.7 million in FY2024. A second program, TTI-109, is also in development. Total operating expenses were $26.7 million in FY2025, composed of $18.0 million in R&D and $8.7 million in general and administrative costs. As of December 31, 2025, Tvardi holds trademark registrations for the "TVARDI" mark across multiple jurisdictions including the United States, European Union, China, Japan, Australia, Korea, and the United Kingdom.

Revenue model

Tvardi Therapeutics generates no product revenue. The company is pre-commercial and finances operations through equity and capital markets transactions. All spending is directed toward clinical-stage drug development.

Products and services

TTI-101 is the lead product candidate, a small-molecule STAT3 inhibitor in clinical trials for HCC, IPF, and mBC as of the 10-K filed March 31, 2026. TTI-109 is a second product candidate in development. Neither product is approved or commercialized.

Customers and end markets

Tvardi has no commercial customers. Target end markets are oncology (hepatocellular carcinoma, metastatic breast cancer) and fibrotic disease (idiopathic pulmonary fibrosis). Patients in these indications would be the ultimate beneficiaries upon any future approval.

Value-chain role

Tvardi operates as a drug discovery and clinical development organization. It relies on third-party contract research organizations, clinical trial sites, and research institutions for preclinical and clinical activities. Manufacturing and certain research functions are outsourced.

Geographic exposure

Tvardi holds trademark registrations in the United States, European Union, China, Japan, Australia, Korea, and the United Kingdom as of December 31, 2025. Clinical and operational geographic footprint is not further detailed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: ANI Pharmaceuticals Inc Atea Pharmaceuticals Inc Edgewise Therapeutics Inc Esperion Therapeutics Inc Evolus Inc Johnson & Johnson Nuvation Bio Inc Phibro Animal Health Corp Rani Therapeutics Holdings Inc Tricida, Inc.